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COMPARING ADHERENCETO FIXED DOSE COMBINATION
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OBJECTIVE: To compare adherence among dyslipidemia
patients initiating on ﬁxed dose combination (FDC) therapy
versus multi-pill combination (MPC) therapies in a managed care
population. METHODS: Using claims data from the HealthCore
Integrated Research Database, study patients 18 years were
identiﬁed as newly-initiating on FDC [Advicor®: niacin extended
release (ERN) + lovastatin] or MPC’s [simvastatin + ERN (ERN/
S), lovastatin + ERN (ERN/L)] between January 1, 2000-June
30, 2006 [index date], with a minimum 6 months pre- and 12
months post-index health plan eligibility. Adherence to dyslipi-
demia therapy was measured using medication possession ratio
(MPR). Multivariate logistic regression was used to estimate
associations between study cohorts and optimal adherence (MPR
80%) while controlling for baseline demographic and clinical
differences. RESULTS: A total of 8988 patients (6638 FDC;
1687 ERN/S; 663 ERN/L) were identiﬁed. Patients initiating
FDC therapy were signiﬁcantly younger [mean (SD) ages of
51.9 (10.5) versus 56.0 (9.4) years [ERN/S] and 56.1 (10.6)
years [ERN/L], respectively, p < 0.01, and comprised of fewer
males (73.1% vs. 83.0% and 77.7%, respectively; p < 0.01 and
p = 0.1). Baseline Deyo-Charlson comorbidity scores were sig-
niﬁcantly lower among FDC patients (0.50  0.9 vs. 0.7  1.1
and 0.6  1.1, respectively; p < 0.01 and p < 0.05). During one-
year follow-up, average MPR was higher among FDC patients
versus both ERN/S and ERN/L patients (0.54  0.35 vs.
0.50  0.35 and 0.47  0.34, respectively; p < 0.01). Multivari-
ate logistic regression showed that ERN/S and ERN/L patients
were 31.3% (95% CI: 22.9%–39.5%) and 39.1% (95% CI:
26.7%–49.4%) less likely to be optimally adherent than FDC
patients, p < 0.01. CONCLUSION: Adherence was signiﬁcantly
higher among FDC-initiated patients versus MPC-initiated dys-
lipidemia therapies in this managed care population. Further
studies in clinical and economic impact of improved adherence to
FDC dyslipidemia therapy are warranted.
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OBJECTIVE: To examine the relationship between 3 measures of
medication adherence for relapsing multiple sclerosis (MS)-
related drug therapy and the likelihood of experiencing a severe
MS relapse. METHODS: Subjects were selected from the PHAR-
Metrics database if they had at least 1 MS drug (Avonex®,
Betaseron®, Copaxone®, Rebif®) claim from January 1, 2000
through December 31, 2004, were continuously eligible for 24
months after their ﬁrst MS-related prescription (index date), and
6 months prior to the index date. Subjects were excluded if the
were <18 or >65 years of age, exposed to Tysabri® after the
index date, had evidence of study medication use in a health care
facility, or if admitted to a long-term care facility. Severe MS
relapse was deﬁned as an MS-related hospitalization or emer-
gency room visit. MS-related medication adherence was mea-
sured by 3 methods: medication possession ratio (MPR),
consistence, and persistence. Covariates included, age, gender,
region of the country, and treatment status (new or existing),
comorbidities, and therapy type (mono- or multi-drug therapy).
RESULTS: Subjects (N = 2388) had a mean age of 43.9 years,
76.7% were new patients, 8.1% had at least 1 severe MS relapse,
and 76.4% were female. All 3 adherence measures were signiﬁ-
cantly associated with severe MS relapse with odds ratios of
0.921 (MPR), 0.946 (persistence), and 0.895 (consistence) indi-
cating that increased adherence is associated with decreased like-
lihood of experiencing a severe MS relapse. Other signiﬁcant
covariates (p < 0.05) in all models were comorbidity and East
region (Mid West reference). Age, gender, and the other regions
were not signiﬁcant at alpha = 0.05. These results are consistent
with previously reported ﬁndings on maximum gap in drug
therapy and likelihood of a severe MS relapse. CONCLUSION:
The relationship between MS-related drug therapy adherence
and the reduced likelihood of a severe MS relapse is consistently
supported across three measures of medication adherence.
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OBJECTIVE: To analyze the impact of formulary restrictions
on adherence to second generation antipsychotics (SGAs).
METHODS: A retrospective cohort study was conducted on data
from a national pharmacy beneﬁt management company covering
January 1, 2004 to December 31, 2005. Patients18 years of age
newly treated with SGAs (aripiprazole, olanzapine, quetiapine,
risperidone, ziprasidone) were followed for up to 1 year after
index prescription. The two cohorts were categorized as: open
formulary (all SGAs on formulary without restriction), and/or
restricted formulary (any SGA not on formulary, or any formulary
SGA requiring step therapy or prior authorization). Logistic
regression was used to determine the main effect of formulary
category on medication adherence (medication possession ratio
[MPR] 0.8) and the probability of changing index medication
regimen (switching to or adding another drug, or discontinuing
index drug), adjusting for co-pay, patient demographics, geo-
graphical location, concomitant medications, index drug and
health plan type. RESULTS: The study sample included 5017
patients (45% male) with a mean age of 46.2 years (SD 16.2).
Patients in open formulary plans were signiﬁcantly more likely
to be adherent than patients in restricted formulary plans
(OR = 1.14, 95%CI: 1.05–1.23), andwere signiﬁcantly less likely
to change their index regimen (OR = 0.91, 95% CI: 0.84–0.99).
Patients in single-tier formularies were signiﬁcantly more likely to
be adherent than those in two-tier formularies (OR = 1.21, 95%
CI: 1.15–1.27) and less likely to change their index regimen
(OR = 0.8, 95% CI: 0.75–0.85). Higher co-pays were associated
with signiﬁcantly lower adherence (OR = 0.95, 95% CI 0.93–
0.98) but a lower likelihood of changing index regimen
(OR = 0.98, 95%CI:0.96–1.00).CONCLUSION: Patients newly
started on SGAs are more adherent and less likely to change their
initial medication regimens on open formulary plans than on
restricted plans. Formulary restrictions may adversely impact
treatment continuity in patients new to SGA therapy.
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